Azacitidine for Treatment of Therapy Related Myelodysplastic Syndrome

被引：0
|
作者：
Komrokji, Rami S. [1 ]
Al Ali, Najla H. [1 ]
Alrawi, E. [1 ]
Padron, Eric [1 ]
Perkins, Janelle [2 ]
Field, Teresa [1 ]
Lancet, Jeffrey E. [1 ]
List, Alan F. [2 ]
机构：
[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：745 / 746
页数：2
相关论文
共 50 条
  • [21] SAFETY PROFILE OF AZACITIDINE IN THE TREATMENT OF THERAPY-RELATED MYELODYSPLASTIC SYNDROMES/ACUTE MYELOID LEUKAEMIA
    Minoia, C.
    Sgherza, N.
    Greco, G.
    Buquicchio, C.
    Loseto, G.
    de Fazio, V.
    Iacobazzi, A.
    Rana, A.
    Merchionne, F.
    Tarantini, G.
    Pavone, V.
    Guarini, A.
    HAEMATOLOGICA, 2014, 99 : 619 - 619
  • [22] Immunomodulatory Effects of Azacitidine Treatment In High Risk Myelodysplastic Syndrome
    Bontkes, Hetty J.
    Alhan, Canan
    Eeltink, Corien
    Westers, Theresia M.
    Ossenkoppele, Gert J.
    Van de Loosdrecht, Arjan A.
    BLOOD, 2010, 116 (21) : 775 - 775
  • [23] Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
    Ritchie, Ellen K.
    CLINICAL INTERVENTIONS IN AGING, 2012, 7 : 165 - 173
  • [24] Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome
    Zeidan, Amer M.
    Borate, Uma
    Pollyea, Daniel A.
    Brunner, Andrew M.
    Roncolato, Fernando
    Garcia, Jacqueline S.
    Filshie, Robin J.
    Odenike, Olatoyosi
    Watson, Anne-Marie
    Krishnadasan, Ravi
    Bajel, Ashish
    Naqvi, Kiran
    Zha, Jiuhong
    Hogdal, Leah
    Zhou, Ying
    Hoffman, David
    Kye, Steve
    Garcia-Manero, Guillermo
    BLOOD, 2021, 138
  • [25] Treatment-related myelodysplastic syndrome: molecular characteristics and therapy
    Bhatia, Ravi
    Deeg, H. Joachim
    CURRENT OPINION IN HEMATOLOGY, 2011, 18 (02) : 77 - 82
  • [26] Novel chromosomal aberration in a patient with myelodysplastic syndrome after therapy with azacitidine
    Athanasiadou, Anastasia
    Papaioannou, George
    Stavroyianni, Niki
    Tsompanakou, Aliki
    Gaitatzi, Maria
    Anagnostopoulos, Achilles
    CHROMOSOME RESEARCH, 2011, 19 : S147 - S147
  • [27] Usefulness of azacitidine therapy in a sickle cell disease patient with myelodysplastic syndrome
    De Luna, Gonzalo
    Darnige, Luc
    Roueff, Stephane
    Peyrard, Thierry
    Pouchot, Jacques
    Arlet, Jean-Benoit
    ANNALS OF HEMATOLOGY, 2020, 99 (03) : 661 - 662
  • [28] Usefulness of azacitidine therapy in a sickle cell disease patient with myelodysplastic syndrome
    Gonzalo De Luna
    Luc Darnige
    Stéphane Roueff
    Thierry Peyrard
    Jacques Pouchot
    Jean-Benoît Arlet
    Annals of Hematology, 2020, 99 : 661 - 662
  • [29] Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment
    Calleja, Anne
    Yun, Seongseok
    Moreilhon, Chimene
    Karsenti, Jean Michel
    Gastaud, Lauris
    Mannone, Lionel
    Komrokji, Rami
    al Ali, Najla
    Dadone-montaudie, Berangere
    Robert, Guillaume
    Auberger, Patrick
    Raynaud, Sophie
    Sallman, David A.
    Cluzeau, Thomas
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (05) : 488 - 498
  • [30] Oral Azacitidine in Patients With Myelodysplastic Syndrome
    Shibusawa, Motoharu
    Kidoguchi, Keisuke
    Tanimoto, Tetsuya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (27) : 3091 - +
12345